Bispecific antibodies for cancer market size to grow by USD 400.72 million between 2022 and 2027; Growth driven by the increasing prevalence of cancer - Technavio

Rhea-AI Summary

The bispecific antibodies for cancer market is projected to grow by USD 400.72 million from 2022 to 2027, with a CAGR of 8.82%, driven by an increasing incidence of cancer and the advantages these antibodies hold over traditional monoclonal antibodies. North America is expected to account for 38% of this growth, especially due to favorable reimbursement schemes. Key trends include an increase in strategic alliances and advancements in bispecific antibody generation platforms, while challenges such as high drug costs and late diagnoses impact market growth.

Positive

• Projected market growth of USD 400.72 million (2022-2027).
• CAGR of 8.82% indicates robust growth prospects.
• North America expected to dominate market growth at 38%.

Negative

• High drug costs could lead to patient non-compliance.
• Late cancer diagnoses contribute to poor survival rates.

NEW YORK, April 3, 2023 /PRNewswire/ -- The bispecific antibodies for cancer market size is forecasted to increase by USD 400.72 million from 2022 to 2027, at a CAGR of 8.82%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of cancer, the advantages of bispecific antibodies over monoclonal antibodies, and a strong pipeline. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download the Sample Report

Vendor Analysis

The global bispecific antibodies for cancer market is fragmented and is characterized largely by global vendors. These vendors are constantly trying to invest in technologies to develop advanced biologic therapeutics, such as monoclonal antibodies, for the treatment of various chronic diseases. The key vendors in the global bispecific antibodies for cancer market are focusing on product approvals, M&A, and product launches to gain a competitive edge. Inorganic growth strategies, robust R&D, and pricing strategies will increase competition among these vendors during the forecast period. Some of the key vendors covered in the report include:

• ABL Bio Inc.: The company offers bispecific antibody solutions for cancer, such as Grabody bispecific antibody platform.
• AFFIMED N.V.: The company offers bispecific antibody solutions for cancer, such as the ROCK platform.
• Akeso Inc.: The company offers bispecific antibody solutions for cancer, such as Ivonescimab.
• Amgen Inc.: The company offers bispecific antibody solutions for cancer.
• Aptevo Therapeutics Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Eli Lilly and Co.
• EPIMAB BIOTHERAPEUTICS INC.
• F STAR THERAPEUTICS INC.
• F. Hoffmann La Roche Ltd.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson
• Mereo BioPharma Group Plc
• Merus N.V.

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get a holistic overview of the biospecific antibodies for cancer market from industry experts to evaluate and develop growth strategies, historic (2017 to 2021) and forecast market size (2023 to 2027). Download the Sample

Market Segmentation:

The market is segmented by type (CD19 or SC3 and CD30 or CD16A), distribution channel (hospitals, retail pharmacies, and online), and geography (North America, Europe, Asia, and Rest of World (ROW)).

• By type, the market growth will be significant in the CD19 or SC3 segment during the forecast period. Bispecific antibodies have several advantages when compared to monoclonal antibodies. They can redirect specific immune cells to the site of the tumor cells to boost tumor killing. In addition, they can potentially increase the binding specificity by interacting with two different cell-surface antigens instead of one. They are also able to block two different pathways that exert unique pathogenesis simultaneously. Such advantages will drive the growth of the segment during the forecast period.
• North America will account for 38% of the market growth during the forecast period. The US is the key country for the bispecific antibodies for cancer market in the region. The growth of this region is attributed to factors such as the availability of reimbursement schemes. Moreover, this region is expected to grow at a faster rate than other regions.

Market Dynamics:

Key Drivers:

• Increasing prevalence of cancer
• Advantages of bispecific antibodies over monoclonal antibodies
• Strong pipeline

Increasing cancer prevalence is especially driving market growth. As cancer is the leading cause of premature death, it causes significant economic setbacks. Rising cancer cases have led to huge investments in oncology. Due to this, government agencies, research institutes, and pharmaceutical companies invest heavily in research and development as well as in cancer treatments. Moreover, the rising investments in cancer treatment will directly lead to a higher demand for supportive care therapy drugs. Therefore, the increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers. These factors, in turn, will drive the global bispecific antibodies for cancer market during the forecast period.

Major Trends:

• Increase in strategic alliances
• Emerging bispecific antibody generation platforms
• Strong R&D in China

The increase in strategic alliances is an important trend in the market. Growing demand for bispecific antibodies to treat various types of cancer has led several start-ups to enter the market, creating opportunities for strategic alliances between mid-sized companies and corporations. For instance, in 2021, Xencor and MD Anderson announced a collaboration to develop novel T Cell-Engaging bispecific antibodies for the treatment of cancer patients. Thus, increasing collaborations will drive the discovery of bispecific antibodies during the forecast period.

Key Challenges:

• High cost of drugs
• Late diagnosis leads to poor survival rates
• Side effects of BLINCYTO

The high cost of drugs is the major challenge impeding the market growth. Patients with a history of cancer are more likely to discontinue treatment due to the high cost of drugs. Successful cancer treatment depends on patient compliance throughout the course of treatment, including chemotherapy, targeted therapy, and immunotherapy. Therefore, high drug costs will challenge the market growth during the forecast period. 

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this Bispecific Antibodies For Cancer Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the bispecific Antibodies for cancer market between 2023 and 2027
• Precise estimation of the bispecific antibodies for cancer market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the bispecific antibodies for cancer market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of bispecific Antibodies for cancer market vendors

Related Reports: 

• The cancer immunotherapy market size is estimated to grow at a CAGR of 14.67% between 2021 and 2026. The addiction therapeutics market size is forecasted to increase by USD 74.45 billion. The market is segmented by type (monoclonal antibodies, cancer vaccines, and checkpoint inhibitors and immunomodulators) and geography (North America, Europe, Asia, and ROW). 
• The anti-CD20 monoclonal antibodies (mAbs) market is expected to develop at the market's growth momentum (CAGR) of 9.81% between 2021 and 2026 and the market size is expected to increase by USD 9.05 billion. The market is segmented by product (oncology, neurology, and immunology) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Bispecific Antibodies For Cancer Market Scope
Report Coverage	Details
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 8.82%
Market growth 2023-2027	USD 400.72 million
Market structure	Fragmented
YoY growth 2022-2023 (%)	6.2
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Ireland, Hungary, China, and India
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global bispecific antibodies for cancer market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global bispecific antibodies for cancer market 2017 - 2021 ($ million)

• 4.2 Type Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)

• 4.3 Distribution channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 30: Chart on Type - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

• 6.2 Comparison by Type
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type

• 6.3 CD19 or CD3 - Market size and forecast 2022-2027
• Exhibit 34: Chart on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on CD19 or CD3 - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on CD19 or CD3 - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on CD19 or CD3 - Year-over-year growth 2022-2027 (%)

• 6.4 CD30 or CD16A - Market size and forecast 2022-2027
• Exhibit 38: Chart on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on CD30 or CD16A - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on CD30 or CD16A - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on CD30 or CD16A - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Type
• Exhibit 42: Market opportunity by Type ($ million)
• Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel
• Exhibit 46: Chart on Comparison by Distribution Channel
• Exhibit 47: Data Table on Comparison by Distribution Channel

• 7.3 Hospitals - Market size and forecast 2022-2027
• Exhibit 48: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
• Exhibit 50: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
• Exhibit 51: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacies - Market size and forecast 2022-2027
• Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

• 7.5 Online - Market size and forecast 2022-2027
• Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share by geography 2022-2027 (%)
• Exhibit 64: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Ireland - Market size and forecast 2022-2027
• Exhibit 87: Chart on Ireland - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Ireland - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Ireland - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Ireland - Year-over-year growth 2022-2027 (%)

• 9.9 China - Market size and forecast 2022-2027
• Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.10 Hungary - Market size and forecast 2022-2027
• Exhibit 95: Chart on Hungary - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Hungary - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Hungary - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Hungary - Year-over-year growth 2022-2027 (%)

• 9.11 India - Market size and forecast 2022-2027
• Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography
• Exhibit 103: Market opportunity by geography ($ million)
• Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered

• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification

• 12.3 ABL Bio Inc.
• Exhibit 111: ABL Bio Inc. - Overview
• Exhibit 112: ABL Bio Inc. - Product / Service
• Exhibit 113: ABL Bio Inc. - Key offerings

• 12.4 AFFIMED N.V.
• Exhibit 114: AFFIMED N.V. - Overview
• Exhibit 115: AFFIMED N.V. - Product / Service
• Exhibit 116: AFFIMED N.V. - Key offerings

• 12.5 Akeso Inc.
• Exhibit 117: Akeso Inc. - Overview
• Exhibit 118: Akeso Inc. - Product / Service
• Exhibit 119: Akeso Inc. - Key offerings

• 12.6 Amgen Inc.
• Exhibit 120: Amgen Inc. - Overview
• Exhibit 121: Amgen Inc. - Product / Service
• Exhibit 122: Amgen Inc. - Key offerings

• 12.7 Aptevo Therapeutics Inc.
• Exhibit 123: Aptevo Therapeutics Inc. - Overview
• Exhibit 124: Aptevo Therapeutics Inc. - Product / Service
• Exhibit 125: Aptevo Therapeutics Inc. - Key offerings

• 12.8 Astellas Pharma Inc.
• Exhibit 126: Astellas Pharma Inc. - Overview
• Exhibit 127: Astellas Pharma Inc. - Product / Service
• Exhibit 128: Astellas Pharma Inc. - Key offerings

• 12.9 Chugai Pharmaceutical Co. Ltd.
• Exhibit 129: Chugai Pharmaceutical Co. Ltd. - Overview
• Exhibit 130: Chugai Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 131: Chugai Pharmaceutical Co. Ltd. - Key offerings

• 12.10 Eli Lilly and Co.
• Exhibit 132: Eli Lilly and Co. - Overview
• Exhibit 133: Eli Lilly and Co. - Product / Service
• Exhibit 134: Eli Lilly and Co. - Key offerings

• 12.11 EPIMAB BIOTHERAPEUTICS INC.
• Exhibit 135: EPIMAB BIOTHERAPEUTICS INC. - Overview
• Exhibit 136: EPIMAB BIOTHERAPEUTICS INC. - Product / Service
• Exhibit 137: EPIMAB BIOTHERAPEUTICS INC. - Key offerings

• 12.12 F STAR THERAPEUTICS INC.
• Exhibit 138: F STAR THERAPEUTICS INC. - Overview
• Exhibit 139: F STAR THERAPEUTICS INC. - Product / Service
• Exhibit 140: F STAR THERAPEUTICS INC. - Key offerings

• 12.13 F. Hoffmann La Roche Ltd.
• Exhibit 141: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 142: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 143: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 144: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 145: F. Hoffmann La Roche Ltd. - Segment focus

• 12.14 Glenmark Pharmaceuticals Ltd.
• Exhibit 146: Glenmark Pharmaceuticals Ltd. - Overview
• Exhibit 147: Glenmark Pharmaceuticals Ltd. - Product / Service
• Exhibit 148: Glenmark Pharmaceuticals Ltd. - Key offerings

• 12.15 Johnson and Johnson
• Exhibit 149: Johnson and Johnson - Overview
• Exhibit 150: Johnson and Johnson - Business segments
• Exhibit 151: Johnson and Johnson - Key news
• Exhibit 152: Johnson and Johnson - Key offerings
• Exhibit 153: Johnson and Johnson - Segment focus

• 12.16 Mereo BioPharma Group Plc
• Exhibit 154: Mereo BioPharma Group Plc - Overview
• Exhibit 155: Mereo BioPharma Group Plc - Product / Service
• Exhibit 156: Mereo BioPharma Group Plc - Key offerings

• 12.17 Merus N.V.
• Exhibit 157: Merus N.V. - Overview
• Exhibit 158: Merus N.V. - Product / Service
• Exhibit 159: Merus N.V. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist
• Exhibit 160: Inclusions checklist
• Exhibit 161: Exclusions checklist

• 13.3 Currency conversion rates for US$
• Exhibit 162: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 163: Research methodology
• Exhibit 164: Validation techniques employed for market sizing
• Exhibit 165: Information sources

• 13.5 List of abbreviations
• Exhibit 166: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/bispecific-antibodies-for-cancer-market-size-to-grow-by-usd-400-72-million-between-2022-and-2027-growth-driven-by-the-increasing-prevalence-of-cancer---technavio-301785737.html

SOURCE Technavio

FAQ

What is the projected growth of the bispecific antibodies for cancer market by 2027?

The bispecific antibodies for cancer market is projected to grow by USD 400.72 million from 2022 to 2027.

What is the expected CAGR for the bispecific antibodies market?

The expected CAGR for the bispecific antibodies market is 8.82% from 2022 to 2027.

Which region will see the most growth in the bispecific antibodies market?

North America is expected to account for 38% of the market growth during the forecast period.

What are the key challenges facing the bispecific antibodies market?

The major challenges include high drug costs and late diagnoses leading to poor survival rates.

What advantages do bispecific antibodies have over monoclonal antibodies?

Bispecific antibodies can redirect immune cells to tumors and interact with multiple antigens, enhancing specificity and effectiveness.